@article{ae1f568592514c09af861a48d011e030,
title = "Detection of Alzheimer's disease using cortical diffusion tensor imaging",
abstract = "The aim of this research was to test a novel in-vivo brain MRI analysis method that could be used in clinical cohorts to investigate cortical architecture changes in patients with Alzheimer's Disease (AD). Three cohorts of patients with probable AD and healthy volunteers were used to assess the results of the method. The first group was used as the “Discovery” cohort, the second as the “Test” cohort and the last “ATN” (Amyloid, Tau, Neurodegeneration) cohort was used to test the method in an ADNI 3 cohort, comparing to amyloid and Tau PET. The method can detect altered quality of cortical grey matter in AD patients, providing an additional tool to assess AD, distinguishing between these and healthy controls with an accuracy range between good and excellent. These new measurements could be used within the “ATN” framework as an index of cortical microstructure quality and a marker of Neurodegeneration. Further development may aid diagnosis, patient selection, and quantification of the “Neurodegeneration” component in response to therapies in clinical trials.",
keywords = "Alzheimer's Disease, cortical diffusion tensor imaging, cortical microstructure, diagnostic accuracy, minicolumn",
author = "{for the Alzheimers Disease Neuroimage Initiative} and Mario Torso and Marco Bozzali and Giovanna Zamboni and Mark Jenkinson and Chance, {Steven A.}",
note = "Funding Information: Marco Bozzali and Giovanna Zamboni report no disclosures. Mario Torso, Mark Jenkinson, and Steven A. Chance have submitted patent applications related to diffusion MRI analysis. Steven A. Chance is a co-founder of a company, Oxford Brain Diagnostics, from which he has received no funding toward the research or preparation of this manuscript. Mark Jenkinson is co-founder of a company, Oxford Brain Diagnostics, from which he has received no funding toward the research or preparation of this manuscript. Statistical Analysis conducted by Dr. Mario Torso, PhD, University of Oxford. Study Funded by an Alzheimer's Research UK grant (ARUK-PPG2017A-19) to Steven A. Chance. Also, the Wellcome Centre for Integrative Neuroimaging is supported by core funding from the Wellcome Trust (203139/Z/16/Z) from which Mark Jenkinson received funding. Mark Jenkinson is also supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). Funding Information: Alzheimer's Research UK, Grant/Award Number: ARUK‐PPG2017A‐19; Wellcome Trust, Grant/Award Number: 203139/Z/16/Z; National Institute for Health Research (NIHR) Funding information Funding Information: Marco Bozzali and Giovanna Zamboni report no disclosures. Mario Torso, Mark Jenkinson, and Steven A. Chance have submitted patent applications related to diffusion MRI analysis. Steven A. Chance is a co‐founder of a company, Oxford Brain Diagnostics, from which he has received no funding toward the research or preparation of this manuscript. Mark Jenkinson is co‐founder of a company, Oxford Brain Diagnostics, from which he has received no funding toward the research or preparation of this manuscript. conducted by Dr. Mario Torso, PhD, University of Oxford. by an Alzheimer's Research UK grant (ARUK‐PPG2017A‐19) to Steven A. Chance. Also, the Wellcome Centre for Integrative Neuroimaging is supported by core funding from the Wellcome Trust (203139/Z/16/Z) from which Mark Jenkinson received funding. Mark Jenkinson is also supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). Statistical Analysis Study Funded ",
year = "2021",
month = mar,
doi = "10.1002/hbm.25271",
language = "English",
volume = "42",
pages = "967--977",
journal = "Human Brain Mapping",
issn = "1065-9471",
publisher = "Wiley-Liss Inc.",
number = "4",
}